Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.

Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction ...

Merck KGaA, Darmstadt, Germany and Bio-Techne Corp., a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, ...

Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota ...

These 8 healthcare stocks delivered strong gains last week. Discover what drove each rally—and why not all rallies are ...

The Financial Times highlights key developments in the business and governance sectors. EasyJet is in discussions with Castlelake after rejecting a £4.9 billion offer. German company Merck is ...

Merck KGaA's agreement to buy Bio-Techne for $11.3 billion strengthens its hold in life sciences, especially drug discovery ...

Bio-Techne rallied for a third straight day on Thursday, surging 20.08 percent to close at $70.70 apiece, as investors ...

Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.

The company is “especially excited” about an immune cell therapy manufacturing technology included in the deal, a Merck KGaA executive said. Merck KGaA has agreed to buy Bio-Techne for $11.3 billion ...

Merck KGaA, Darmstadt, Germany, has agreed to acquire Bio-Techne for approximately $11.3 billion, the companies said today, in a deal designed to position the buyer as more of a leader across the life ...

By Christy Santhosh, Padmanabhan Ananthan and Bhanvi Satija June 25 (Reuters) - German drugmaker Merck KGaA said on Thursday ...